Neurogene Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Neurogene Inc. (NGNE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.86M, a 130.69% increase year-over-year.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.63M, a 10.35% decline year-over-year.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.37M, a 36.01% increase year-over-year.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.41M, a 47.28% increase year-over-year.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.18M, a 70.47% increase from fiscal 2024.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.32M, a 486.74% increase from fiscal 2023.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.42M, a 13.26% increase from fiscal 2022.
- Neurogene Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.25M, a 89.17% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 2 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 10 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.86M 10-Q · filed 2026-08-11 | $11.49M derived: sum of 2 quarters · filed 2026-08-11 | ||||||
| 2026-03-31 | $3.63M 10-Q · filed 2026-08-11 | |||||||
| 2025-12-31 | $14.18M 10-K · filed 2026-03-24 | |||||||
| 2025-09-30 | $3.37M 10-Q · filed 2025-11-13 | $6.77M derived: sum of 2 quarters · filed 2026-08-11 | $10.82M derived: sum of 3 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | $3.41M 10-Q · filed 2026-08-11 | $7.46M derived: sum of 2 quarters · filed 2026-08-11 | ||||||
| 2025-03-31 | $4.05M 10-Q · filed 2026-08-11 | |||||||
| 2024-12-31 | $8.32M 10-K · filed 2026-03-24 | |||||||
| 2024-09-30 | $2.47M 10-Q · filed 2025-11-13 | $4.79M derived: sum of 2 quarters · filed 2025-11-13 | $5.83M derived: sum of 3 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $2.31M 10-Q · filed 2025-11-13 | $3.36M derived: sum of 2 quarters · filed 2025-11-13 | ||||||
| 2024-03-31 | $1.04M 10-Q · filed 2025-11-13 | |||||||
| 2023-12-31 | $1.42M 10-K · filed 2024-03-18 | |||||||
| 2023-09-30 | $386.00K 10-Q · filed 2024-11-18 | $172.00K 10-Q · filed 2023-11-14 | $770.00K derived: sum of 2 quarters · filed 2024-11-18 | $1.06M derived: sum of 3 quarters · filed 2024-11-18 | ||||
| 2023-06-30 | $384.00K 10-Q · filed 2024-11-18 | $331.00K 10-Q · filed 2023-08-10 | $677.00K derived: sum of 2 quarters · filed 2024-11-18 | |||||
| 2023-03-31 | $293.00K 10-Q · filed 2024-11-18 | $1.19M 10-Q · filed 2023-05-08 | ||||||
| 2022-12-31 | $1.25M 10-K · filed 2024-03-18 | $8.83M 10-K · filed 2023-03-20 | ||||||
| 2022-09-30 | $2.03M 10-Q · filed 2023-11-14 | $4.34M derived: sum of 2 quarters · filed 2023-11-14 | $6.79M derived: sum of 3 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | $2.31M 10-Q · filed 2023-11-14 | $4.76M derived: sum of 2 quarters · filed 2023-11-14 | ||||||
| 2022-03-31 | $2.45M 10-Q · filed 2023-11-14 | |||||||
| 2021-12-31 | $11.56M 10-K · filed 2023-03-20 | |||||||
| 2021-09-30 | $3.21M 10-Q · filed 2022-11-14 | $6.13M derived: sum of 2 quarters · filed 2022-11-14 | $8.55M derived: sum of 3 quarters · filed 2022-11-14 | |||||
| 2021-06-30 | $2.92M 10-Q · filed 2022-11-14 | $5.34M derived: sum of 2 quarters · filed 2022-11-14 | ||||||
| 2021-03-31 | $2.42M 10-Q · filed 2022-11-14 | |||||||
| 2020-12-31 | $5.62M 10-K · filed 2022-03-01 | |||||||
| 2020-09-30 | $1.69M 10-Q · filed 2021-11-04 | $2.71M derived: sum of 2 quarters · filed 2021-11-04 | $3.39M derived: sum of 3 quarters · filed 2021-11-04 | $4.06M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $1.02M 10-Q · filed 2021-11-04 | $1.71M derived: sum of 2 quarters · filed 2021-11-04 | $2.37M derived: sum of 3 quarters · filed 2021-11-04 | $7.52M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-03-31 | $683.00K 10-Q · filed 2021-11-04 | $1.35M derived: sum of 2 quarters · filed 2021-11-04 | $6.50M derived: sum of 3 quarters · filed 2021-11-04 | $7.29M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2019-12-31 | $666.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $5.82M derived: sum of 2 quarters · filed 2021-03-25 | $6.61M derived: sum of 3 quarters · filed 2021-03-25 | $7.68M 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $5.15M 10-Q · filed 2020-11-09 | $5.94M derived: sum of 2 quarters · filed 2020-11-09 | $7.02M 10-Q · filed 2019-11-13 | $7.85M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $788.00K 10-Q · filed 2020-11-09 | $1.87M 10-Q · filed 2019-08-01 | $2.70M derived: sum of 3 quarters · filed 2020-11-09 | $3.74M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-03-31 | $1.08M 10-Q · filed 2020-11-09 | $1.92M derived: sum of 2 quarters · filed 2020-11-09 | $2.95M derived: sum of 3 quarters · filed 2020-11-09 | $4.46M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2018-12-31 | $837.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.87M derived: sum of 2 quarters · filed 2020-03-12 | $3.39M derived: sum of 3 quarters · filed 2020-03-12 | $4.70M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $1.04M 10-Q · filed 2019-11-13 | $2.55M derived: sum of 2 quarters · filed 2019-11-13 | $3.86M 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $1.51M 10-Q · filed 2019-08-01 | $2.83M 10-Q · filed 2019-08-01 | ||||||
| 2018-03-31 | $1.31M 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | $3.84M 10-K · filed 2020-03-12 | |||||||
| 2016-12-31 | $1.97M 10-K · filed 2019-03-07 | |||||||
| 2015-12-31 | $1.51M 10-K · filed 2018-03-12 | |||||||
| 2014-12-31 | $754.77K 10-K · filed 2015-03-16 | $855.00K 10-K · filed 2017-03-09 | ||||||
| 2014-03-12 | $99.42K 10-K · filed 2015-03-16 | |||||||
| 2013-12-31 | $349.00K 10-K · filed 2016-03-14 | $349.32K 10-K · filed 2015-03-16 | ||||||
| 2012-12-31 | $351.32K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |